Agendia
Agendia is a privately held molecular diagnostics company that develops and commercializes the FDA-cleared MammaPrint and CE-marked BluePrint genomic tests to help oncologists personalize early-stage breast cancer treatment decisions, serving healthcare providers and patients globally.
- Company typePrivate
- Founded2003
- HeadquartersAmsterdam, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Agendia does
Agendia is a privately held molecular diagnostics company founded in 2003 by Prof. Laura van 't Veer and Prof. René Bernards at the Netherlands Cancer Institute, dual-headquartered in Amsterdam (Netherlands) and Irvine, California (US), with 101–250 employees. The company develops and commercializes genomic tests for early-stage breast cancer, principally the FDA-cleared and CE-marked MammaPrint 70-gene expression profiling test (recurrence risk) and the CE-marked BluePrint 80-gene molecular subtyping test. Both tests are run on microarray and next-generation sequencing technology from a single tumor sample, with results returned within 6 business days; the combined suite analyzes over 150 genes covering all 10 Hallmarks of Cancer and is indicated across Stage I–III disease including node-positive patients.
The company's commercial model is built on direct sales to healthcare providers — oncologists, breast surgeons, and pathologists — who order tests through regional provider portals, email, or fax, with billing handled directly via CMS Medicare and most US commercial health plans plus select European public healthcare systems. Reimbursement covers the one-time per-test fee, and four financial support programs address uninsured patients. Agendia supplements provider-facing GTM with a patient pull-through motion via partnerships with advocacy organizations (Susan G. Komen, Living Beyond Breast Cancer, Tigerlily Foundation, Learn Look Locate, Dandelion Toolkit), educational content, and a breast cancer blog. Over 20+ years, the company has built a deep evidence base including the MINDACT trial (New England Journal of Medicine, 2016), the prospective FLEX Study (20,000+ enrolled of a 30,000-patient goal across 107 sites), 200+ research collaborations, and hundreds of peer-reviewed publications, with multiple ongoing Phase III trials (DEBRA, SWOG S2206, LESS, PROOFS, INSIGHT, I-SPY2) reinforcing clinical guideline inclusion.
Agendia firmographics
Firmographics- Name
- Agendia
- Legal name
- Agendia, Inc.
- Website
- https://agendia.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Agendia is a privately held molecular diagnostics company that develops and commercializes the FDA-cleared MammaPrint and CE-marked BluePrint genomic tests to help oncologists personalize early-stage breast cancer treatment decisions, serving healthcare providers and patients globally.
- Ownership category
- akta.pro rank
Agendia industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Breast Oncology (HLAKAFAJ)
- akta.pro secondary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where Agendia is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Agendia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- MammaPrint Test: One-time genomic test for early-stage breast cancer patients that analyzes tumor tissue from core needle biopsy or surgical resection. Results inform treatment decisions including chemotherapy benefit and endocrine therapy planning. Reimbursed by CMS (Medicare) and most commercial health plans in the US.
- BluePrint Test: One-time molecular subtyping test that classifies tumors into molecular subtypes. Performed alongside or independently of MammaPrint. Also reimbursed by Medicare and commercial insurers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time | Test pricing varies by region and insurance coverage |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Agendia product offering
Product offeringCore offering
Agendia provides clinical genomic diagnostic testing services for early-stage breast cancer, anchored by its MammaPrint 70-gene recurrence risk test and BluePrint 80-gene molecular subtyping test. Both tests are run from a single tumor tissue sample in Agendia's CLIA-regulated, CAP-accredited laboratories and produce combined results within 6 business days to help oncologists, surgeons, and pathologists personalize treatment decisions including chemotherapy benefit, endocrine therapy planning, and identification of aggressive tumor subtypes.
Product overview
Agendia offers a genomic test suite consisting of two FDA-cleared and CE-marked tests for early-stage breast cancer: MammaPrint (70-gene signature) and BluePrint (80-gene signature). Together, these tests analyze over 150 genes from a single tumor sample to provide comprehensive genomic profiling that determines recurrence risk and molecular subtype within 6 business days. The test suite helps physicians personalize treatment decisions including chemotherapy benefit, endocrine therapy duration, and identification of aggressive tumor subtypes.
Differentiator
Problem solved
Functional benefit
Brands
- MammaPrint: FDA-cleared and CE-marked 70-gene expression profiling test that determines risk of breast cancer recurrence (UltraLow Risk, Low Risk, High Risk 1, High Risk 2). Analyzes the 70 most important genes associated with breast cancer recurrence.
- BluePrint
Products and services
- MammaPrint FDA-cleared and CE-marked 70-gene expression profiling test that analyzes breast tumor tissue to determine the risk of cancer recurrence, stratifying patients into UltraLow Risk, Low Risk, High Risk 1, and High Risk 2 categories to guide chemotherapy benefit and treatment planning decisions for early-stage breast cancer patients.
- BluePrint CE-marked 80-gene molecular subtyping test that classifies breast tumors into Luminal-Type, HER2-Type, or Basal-Type molecular subtypes to reveal the underlying biology driving tumor growth and guide personalized treatment planning. Performed exclusively by Agendia in its CLIA-regulated, CAP-accredited laboratory.
- MammaPrint + BluePrint Test Suite Combined genomic testing from a single tumor block that interrogates over 150 genes containing information on tumor aggression and growth potential, providing both MammaPrint recurrence risk and BluePrint molecular subtype results within 6 business days for early-stage breast cancer treatment planning.
Quantifiable outcome
- 46% of clinically high-risk patients reclassified as MammaPrint Low Risk and able to forgo chemotherapy without compromising outcomes
- +6 more outcomes
Companies that use Agendia
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Agendia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Agendia partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Vanderbilt University Medical CentercoreResearch collaboration on genomic testing studies. Researchers at Vanderbilt Health and Agendia co-published study in npj Breast Cancer finding higher prevalence of high-risk breast cancer in Black women. Study analyzed 1,018 women using MammaPrint and BluePrint genomic testing technologies.
- National Cancer Institute (NCI)coreNCI-sponsored SWOG S2206 Phase III trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for MammaPrint High Risk 2 HR+/HER2- breast cancer. NCI-funded network including Alliance, ECOG-ACRIN, and NRG Oncology.
- NRG OncologycoreSponsor of DEBRA Phase III trial evaluating breast conservation surgery with and without radiation in MammaPrint Low Risk patients. Collaborator with National Cancer Institute.
- UNICANCERcoreSponsor of LESS study evaluating de-escalation of adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer and MammaPrint Ultra Low Risk. Up to 50 French sites.
- West German Study GroupcoreSponsor of PROOFS Registry study evaluating endocrine therapy in pre- and perimenopausal luminal early breast cancer patients with MammaPrint Low Risk.
- Susan G. Komen Breast Cancer FoundationcoreCollaborator on INSIGHT Trial evaluating impact of 2nd line chemotherapy on survival in patients with non-Luminal A HR+ metastatic breast cancer using Blueprint and MammaPrint gene expression profiling tests.
- I-SPY2 Trial NetworkcoreAdaptive platform trial employing master framework allowing multiple treatments to be studied in parallel. Agendia contributes genomic profiling to guide treatment evaluation.
- EORTC (European Organization for Research and Treatment of Cancer)coreSponsor of MINDACT Phase III trial demonstrating MammaPrint's ability to safely de-escalate chemotherapy in clinically high-risk, MammaPrint Low Risk early-stage breast cancer patients.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Agendia competitors and assessment
Company assessmentDirect peers
- Exact Sciences: Owner of the Oncotype DX Breast Recurrence Score test, the leading genomic assay for early-stage breast cancer treatment planning. Most direct competitor to MammaPrint, with broader indication coverage and substantially larger commercial scale.
- NanoString Technologies: Developer of the Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50-based), a direct competitor providing breast cancer subtype and recurrence risk classification from FFPE tissue. Competes head-to-head with MammaPrint/BluePrint in the same indication.
Broad incumbents
- Veracyte: Genomic diagnostics company spanning multiple indications (urology, thyroid, breast) including Prosigna-related assets and broader oncology decision-support. Larger and more diversified than Agendia, with overlapping breast cancer genomic testing.
- Myriad Genetics: Established molecular diagnostics company with oncology and women's health testing (including BRACAnalysis and risk-of-recurrence assays). Larger scale and broader indication footprint, with overlapping oncology sales channels and shared leadership pedigree with Agendia (Agendia's CCO previously at Myriad).
- NeoGenomics: Oncology-focused clinical laboratory services company offering comprehensive cancer genomic profiling across solid tumors. Serves similar hospital and oncologist customers and overlaps with Agendia on certain oncology biomarker testing.
- Caris Life Sciences: Provider of comprehensive molecular profiling services (MI Profile, Caris Assure) used by oncologists for therapy selection. Comparable in serving oncologists with tumor profiling data, with a much broader indication footprint than Agendia.
- Tempus AI: AI-enabled precision medicine platform offering multi-modal molecular profiling (DNA, RNA, imaging) for oncology. Competes for the same oncologist decision-support wallet with broader data and analytics capabilities than Agendia.
- Hologic: Women's health diagnostics leader (including breast cancer screening and biopsy systems). Adjacent rather than directly competitive, but operates in the same breast cancer diagnostic workflow and could be a strategic acquirer of genomic testing assets.
Emerging players
- Guardant Health: Liquid biopsy leader (Guardant360, Guardant Reveal) expanding into breast cancer minimal residual disease and treatment monitoring. Represents the emerging blood-based alternative that could pressure Agendia's tissue-based testing model over time.
- Natera: Cell-free DNA testing company (Signatera) with growing presence in MRD and breast cancer recurrence monitoring. Represents the emerging blood-based competitive threat to Agendia's tissue-based recurrence risk testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Agendia social profiles
Digital presenceAgendia compliance and trust
Trust signalCompliance3 records
Agendia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Agendia leadership team
Management profileNumber of profiles
Profiles19 records
Agendia funding detail
Funding detailFunding overview
Funding rounds9 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Agendia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Agendia
What does Agendia do?
Agendia provides clinical genomic diagnostic testing services for early-stage breast cancer, anchored by its MammaPrint 70-gene recurrence risk test and BluePrint 80-gene molecular subtyping test. Both tests are run from a single tumor tissue sample in Agendia's CLIA-regulated, CAP-accredited laboratories and produce combined results within 6 business days to help oncologists, surgeons, and pathologists personalize treatment decisions including chemotherapy benefit, endocrine therapy planning, and identification of aggressive tumor subtypes.
Is Agendia a public or private company?
Agendia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Agendia founded?
Agendia was founded in 2003. It employs 101 to 250 people.
Where is Agendia based?
Agendia is headquartered in Amsterdam, Netherlands, in the Europe region.
How does Agendia make money?
Two revenue lines are on record. MammaPrint Test is the primary driver. The others are bluePrint Test.
Who are Agendia's main competitors?
Direct peers on record are Exact Sciences and NanoString Technologies. Broad incumbents are Veracyte, Myriad Genetics, NeoGenomics, Caris Life Sciences, Tempus AI and Hologic. Emerging players are Guardant Health and Natera.
Does Agendia have an API?
No public API is recorded for Agendia.
What industry is Agendia in?
Agendia's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.